Nucleic acid aptamers have attained significant prominence in diagnostics, therapeutics, and medical research owing to their affinity towards multiple molecular targets. Researchers have delved into the realm of aptamer research and their potential clinical applications, encompassing their prospects for treating a diverse array of orthopedic diseases. Although they can serve as an efficient and safe means for therapeutic delivery, further investigations regarding aptamer screening and production cost reduction are requisite.

A Genomic Press Interview reveals how Professor Alexei Verkhratsky, University of Manchester neurophysiologist, revolutionized understanding of brain communication through glial ionic excitability discoveries. His groundbreaking research demonstrates that neuroglial structural atrophy and functional asthenia mediate synaptic malfunction and neuronal damage in a wide spectrum of brain disorders from neuropsychiatric diseases to neurodegenerative pathologies. This paradigm shift offers unprecedented therapeutic strategies targeting brain homeostatic mechanisms residing mainly in neuroglia.